{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:48:50Z","timestamp":1787240930898,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Objective: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a significant component of demyelinating diseases in pediatric populations. Recently, diagnostic criteria for MOGAD were established. This study aims to evaluate and compare the diagnostic efficacy of the fixed-cell-based assay (Fixed-CBA) and the live cell-based assay (Live-CBA) in patients who meet the 2023 clinical diagnostic criteria for MOGAD. Methods: This retrospective study included patients suspected of having MOGAD who were enrolled between June 2023 and June 2024. Patients were selected based on the \u201ccore clinical demyelinating events\u201d outlined in the 2023 proposed criteria of the International MOGAD Panel. Patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) with aquaporin-4 antibody-positive (AQP4-Abs-positive), and non-central nervous system (non-CNS) inflammatory diseases were chosen as controls. Serum samples were simultaneously tested for MOG-Abs using Fixed-CBA and Live-CBA. Results: A total of 86 patients were enrolled in the study: 52 in the suspected MOGAD group and 34 in the control group. Out of these patients studied, 16 presented with optic neuritis (ON), 5 with myelitis, 8 with acute disseminated encephalomyelitis (ADEM), and 7 with cortical encephalitis. Sixteen patients could not be classified by clinical phenotype. The highest MOG-Ab positivity rate was among patients with cortical encephalitis [85.7% (Live-CBA)\/71.4% (Fixed-CBA)]. Both assays identified 22 positive samples, with Fixed-CBA and Live-CBA sensitivities at 44.2% and 55.8%, respectively, and a specificity of 97%. Of the patients suspected of having MOGAD, 19 cases were confirmed using the Fixed-CBA, while 28 cases were confirmed using the Live-CBA. This resulted in an upgrade in diagnostic classification for nine cases. This led to a diagnostic reclassification in nine cases. Conclusions: Both the Fixed-CBA and Live-CBA were associated with higher sensitivity for patients selected based on the 2023 MOGAD clinical diagnostic criteria. The Live-CBA exhibited an 11.6% increase in sensitivity, contributing to a 17.3% (9\/52) enhancement in clinical diagnostic accuracy.<\/jats:p>","DOI":"10.3390\/diagnostics16010157","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:40:53Z","timestamp":1767602453000},"page":"157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Live-Cell-Based Assay Outperforms Fixed Assay in MOGAD Diagnosis: A Retrospective Validation Against the 2023 International Criteria"],"prefix":"10.3390","volume":"16","author":[{"given":"Anna","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2657-8313","authenticated-orcid":false,"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhan","sequence":"additional","affiliation":[{"name":"V-Medical Laboratory Co., Ltd., Hangzhou 311122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-9000","authenticated-orcid":false,"given":"Wenhan","family":"Li","sequence":"additional","affiliation":[{"name":"V-Medical Laboratory Co., Ltd., Hangzhou 311122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-2992","authenticated-orcid":false,"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotun","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children\u2019s Hospital, Capital Medical University, National Centre for Children\u2019s Health, Beijing 100045, China"},{"name":"Xinjiang Hospital of Beijing Children\u2019s Hospital, Urumqi 830054, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: Part 5 e Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"Majed","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Marchionatti, A., Hansel, G., Avila, G.U., and Sato, D.K. (2021). Detection of MOG-IgG in Clinical Samples by Live Cell-Based Assays: Performance of Immunofluorescence Microscopy and Flow Cytometry. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.642272"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e200183","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of MOG-IgG Testing is Key to 2023 MOGAD Diagnostic Criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105150","DOI":"10.1016\/j.msard.2023.105150","article-title":"Utility of the 2023 international MOGAD panelproposed criteria in clinical practice: An institutional cohort","volume":"81","author":"Alaboudi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"ref_8","first-page":"1184329486","article-title":"The positive predictive value of MOG-IgG testing based on the 2023 diagnostic criteria for MOGAD","volume":"10","author":"Nguyen","year":"2024","journal-title":"Mult. Scler. J.-Exp. Transl. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/13524585251313744","article-title":"Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how","volume":"31","author":"Budhram","year":"2025","journal-title":"Mult. Scler."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: A comparative study","volume":"267","author":"Gastaldi","year":"2020","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2023-333227","article-title":"Validation of the international MOGAD panel proposed criteria: A single-centre US study","volume":"95","author":"Filippatou","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1474-4422(22)00520-8","article-title":"MOGAD comes of age with new criteria","volume":"22","author":"Graus","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hor, J.Y., and Fujihara, K. (2023). Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: A review of prevalence and incidence worldwide. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1260358"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pandit, L., DCunha, A., Malli, C., and Sudhir, A. (2023). Comparison of live and fixed cell-based assay performance: Implications for the diagnosis of MOGAD in a low-middle income country. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1252650"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain A J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pediatrneurol.2023.12.018","article-title":"Encephalitis is an Important Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Diseases: A Single-Center Cohort Study","volume":"152","author":"Ren","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"577653","DOI":"10.1016\/j.jneuroim.2021.577653","article-title":"Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review","volume":"358","author":"Gombolay","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.03.006","article-title":"Prolonged Fever: An Atypical Presentation in MOG Antibody-Associated Disorders","volume":"122","author":"Udani","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1418","DOI":"10.1212\/WNL.0000000000206820","article-title":"Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00431-025-06071-2","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis without cerebral parenchyma involvement on MRI: A single-centre paediatric cohort study","volume":"184","author":"Changhong","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Current understanding and challenges","volume":"270","author":"Chen","year":"2023","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sechi, E., Cacciaguerra, L., Chen, J.J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A.S., Pittock, S.J., and Flanagan, E.P. (2022). Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.885218"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Giglhuber","year":"2024","journal-title":"J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101459","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_28","first-page":"e985","article-title":"Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder","volume":"100","author":"Waltz","year":"2023","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/clinchem\/hvaa254","article-title":"Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis","volume":"66","author":"Budhram","year":"2020","journal-title":"Clin. Chem."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:49:43Z","timestamp":1767602983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diagnostics16010157"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16010157","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}